Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors

Antiviral Therapy

Volumn 19, Issue 7, 2014, Pages 669-677

  Bam, Rujuta A ^a   Birkus, Gabriel ^a   Babusis, Darius ^a   Cihlar, Tomas ^a   Yant, Stephen R ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ANTIVIRUS AGENT; CARBOXYPEPTIDASE C; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS 1 REVERSE TRANSCRIPTASE INHIBITOR; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZIDOVUDINE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GS-7340;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD DONOR; CD4+ T LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MACROPHAGE; MALE; MASS SPECTROMETRY; MONOCYTE DERIVED MACROPHAGE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); T LYMPHOCYTE ACTIVATION; ANALOGS AND DERIVATIVES; CELL CULTURE; CHEMISTRY; DONOR; DRUG EFFECTS; ENZYME ACTIVATION; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MONONUCLEAR CELL;

ADENINE; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CATHEPSIN A; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; ENZYME ACTIVATION; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; TISSUE DONORS;

EID: 84920127695     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2767     Document Type: Article

References (36)

1. Balzarini J, Holy A, Jindrich J, et al. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother 1993; 37:332-338.
2. Balzarini J, Aquaro S, Perno C F, Witvrouw M, Holý A, De Clercq E. Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem Biophys Res Commun 1996; 219:337-341.
3. Palmer S, Margot N, Gilbert H, Shaw N, Buckheit R, Miller M. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance. AIDS Res Hum Retroviruses 2001; 17:1167-1173.
4. Krejčová R, Horská K, Votruba I, Holý A. Phosphorylation of purine (phosphonomethoxy)alkyl derivatives by mitochondrial Amp kinase (Ak2 type) from L1210 cells. Collect Czech Chem Comm 2000; 65:1653-1668.
5. Robbins BL, Wilcox CK, Fridland A, Rodman JH. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy 2003; 23:695-701.
6. Suo Z, Johnson KA. Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-phosphonylmethoxypropyl)adenine. J Biol Chem 1998; 273:27250-27258.
7. Cherrington JM, Allen SJ, McKee BH, Chen MS. Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2 phosphonylmethoxypropyl)cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases beta and gamma. Biochem Pharmacol 1994; 48:1986-1988.
8. Deeks SG, Barditch-Crovo P, Lietman PS, et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel antihuman immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother 1998; 42:2380-2384.
9. Lee WA, Martin JC. Perspectives on the development of acyclic nucleotide analogs as antiviral drugs. Antiviral Res 2006; 71:254-259.
10. Antoniou T, Park-Wyllie LY, Tseng AL. Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection. Pharmacotherapy 2003; 23:29-43.
11. Grim SA, Romanelli F. Tenofovir disoproxil fumarate. Ann Pharmacother 2003; 37:849-859.
12. Permpalung N, Putcharoen O, Avihingsanon A, Ruxrungtham K. Treatment of HIV infection with once-daily regimens. Expert Opin Pharmacother 2012; 13:2301-2317.
13. Eisenberg EJ, He GX, Lee WA. Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood. Nucleosides Nucleotides Nucleic Acids 2001; 20:1091-1098.
14. Lee WA, He GX, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 2005; 49:1898-1906.
15. Lee WA, He G, Mulato A, et al. In vivo and in vitro characterization of GS 7340, an isopropylalaninyl phenyl ester prodrug of tenofovir: selective intracellular activation of GS 7340 leads to preferential distribution in lymphatic tissues. 9th Conference on Retroviruses and Opportunistic Infections. 24-28 February 2002, Seattle, WA, USA. Poster 384-T.
16. Callebaut C, Margot NA, Miller MD. Resistance and potency of GS-7340, a next-generation tenofovir prodrug. Antivir Ther 2012; 17 Suppl 1:A57.
17. Ruane PJ, Dejesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide (TAF) as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr 2013; 63:449-455.
18. Zolopa A, Ortiz R, Sax P, et al. Comparative study of tenofovir alafenamide vs tenofovir disoproxil fumarate each with elvitegravir, cobicistat, and emtricitabine, for HIV treatment. 20th Conference on Retroviruses and Opportunistic Infections. 3-6 March 2013, Atlanta, GA, USA. Abstract 99LB.
19. Margot N, Liu Y, Babusis D, Miller MD, Callebaut C. Antiviral activity of tenofovir alafenamide (TAF) against major NRTI-resistant viruses: improvement over TDF/TFV is driven by higher TFV-DP loading in target cells. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. 4-8 June 2013, Toronto, Canada. Abstract 23.
20. Birkus G, Wang R, Liu X, et al. Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob Agents Chemother 2007; 51:543-550.
21. Birkus G, Kutty N, He GX, et al. Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol 2008; 74:92-100.
22. Birkus G, Bam RA, Frey CR, et al. Intracellular activation pathways for GS-7340 and the effect of antiviral protease inhibitors. 19th Conference on Retroviruses and Opportunistic Infections. 5-8 March 2012, Seattle, WA, USA. Abstract J-115.
23. Satake A, Itoh K, Shimmoto M, Saido TC, Sakuraba H, Suzuki Y. Distribution of lysosomal protective protein in human tissues. Biochem Biophys Res Commun 1994; 205:38-43.
24. Chapman H, Kernan M, Prisbe E, et al. Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340. Nucleosides Nucleotides Nucleic Acids 2001; 20:621-628.
25. Van Rompay KKA, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008; 52:3144-3160.
26. Yee JK, Friedmann T, Burns JC. Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 1994; 43:99-112.
27. Schacker T, Little S, Connick E, et al. Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis 2001; 183:555-562.
28. Fauci AS. Immunopathogenesis of HIV infection. J Acquir Immune Defic Syndr 1993; 6:655-662.
29. Biancotto A, Iglehart SJ, Vanpouille C, et al. HIV-1 induced activation of CD4+ T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivo. Blood 2008; 111:699-704.
30. Pace MJ, Graf EH, Agosto LM, et al. Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog 2012; 8:e1002818.
31. Schmid H, Sauerbrei R, Schwarz G, Weber E, Kalbacher H, Driessen C. Modulation of the endosomal and lysosomal distribution of cathepsins B, L and S in human monocytes/macrophages. Biol Chem 2002; 383:1277-1283.
32. Delaugerre C, Roudiere L, Peytavin G, Rouzioux C, Viard JP, Chaix ML. Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF. J Clin Virol 2005; 32:241-244.
33. White KL, Chen JM, Feng JY, et al. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir Ther 2006; 11:155-163.
34. Sluis-Cremer N, Sheen CW, Zelina S, Torres PS, Parikh UM, Mellors JW. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2007; 51:48-53.
35. Siliciano JD, Siliciano R F. HIV-1 eradication strategies: design and assessment. Curr Opin HIV AIDS 2013; 8:318-325.
36. Cihlár T, Rosenberg I, Votruba I, Holý A. Transport of 9-(2-phosphonomethoxyethyl) adenine across plasma membrane of HeLa S3 cells is protein mediated. Antimicrob Agents Chemother 1995; 39:117-124.